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Objectives This study sought to determine the association of chronic kidney disease (CKD) with high ankle brachial index
(ABI) measurement and to compare its strength with that of CKD with a low ABI.
Background CKD is an important risk factor for cardiovascular disease (CVD) events. A high ABI, a marker of lower extremity
arterial stiffness, is associated with CVD events and mortality. The association between CKD and high ABI is un-
known.
Methods The CHS (Cardiovascular Health Study) enrolled community-living people 65 years of age and measured kidney
function and ABI. Glomerular filtration rate (GFR) was estimated using equations that incorporated either cysta-
tin C or creatinine, and CKD was defined by estimated GFR 60 ml/min/1.73 m2. The ABI was categorized as
low (0.90), low-normal (0.90 to 1.09), normal (1.10 to 1.40), and high (1.40 or incompressible). Multinomial
logistic regression was used to evaluate the associations of CKD with ABI categories.
Results Among 4,513 participants, 23% had CKD, 13% had a low ABI, and 3% had a high ABI. In models adjusted
for age, sex, race, hypertension, diabetes, smoking, body mass index, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and C-reactive protein, cystatin C-based CKD was associated with both
low ABI (relative risk [RR]: 2.0; 95% confidence interval [CI]: 1.6 to 2.5; p 0.001) and high ABI (RR: 1.6;
95% CI: 1.0 to 2.3; p  0.03). Results were similar when CKD was defined by creatinine.
Conclusions CKD is associated with both the high and the low extremes of ABI in community-living older people. Future
studies should evaluate whether arterial stiffness is an important mechanism leading to CVD in people with
CKD. (J Am Coll Cardiol 2009;54:1176–84) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.017t
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Ghronic kidney disease (CKD) affects approximately 13% of
dults in the U.S. (1), and is strongly associated with
ardiovascular disease (CVD) events and all-cause mortality
2). These associations are not fully explained by traditional
VD risk factors, and are detected even with modest
ecrements in kidney function (2,3). At each stage of CKD,
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edicine, Department of Family and Preventive Medicine, and the ‡Division of
ardiology, Department of Medicine, University of California San Diego, San Diego,
alifornia; §Nephrology Section, Veterans Affairs San Diego Healthcare System, San
iego, California; Collaborative Health Studies Coordinating Center, Department
f Biostatistics, and ¶Division of Nephrology, Department of Medicine, University of
ashington, Seattle, Washington; #Nephrology Section, Veterans Affairs Puget
ound Healthcare System, Seattle, Washington; **Department of Epidemiology,
niversity of Pittsburgh, Pittsburgh, Pennsylvania; ††Division of Nephrology,
epartment of Medicine, Tufts-New England Medical Center, Boston, Massachu-etts; ‡‡Department of Medicine, University of California San Francisco, San
rancisco, California; and the §§General Medicine Section, San Francisco Veterans ahe risk of CVD mortality is several-fold higher than the
isk of progression to end-stage renal disease (4). Despite
ntense investigation (5), the mechanisms responsible re-
ain largely unknown.
Arterial calcification is one potential mechanism linking
KD and CVD. Arterial calcification is highly prevalent in
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September 22, 2009:1176–84 CKD and the Spectrum of ABIaintenance dialysis patients (6–8), and its presence and
everity predict all-cause mortality (9,10). However, vascular
alcification may be caused by either intimal or medial
rterial calcification (11,12). As part of the atherosclerotic
rocess, calcium is deposited within the tunica intima with
ipid-rich plaque and focal arterial narrowing. Alternatively,
edial arterial calcification is limited to the tunica media,
as a uniform character resembling a ring in vessel cross-
ection and tram-tracks in longitudinal view, is not inflam-
atory or flow limiting (12), and directly contributes to
rterial stiffness in animal models (13,14). Medial arterial
alcification is particularly prevalent in the distal arteries of
he lower extremities and is correlated with higher pulse-
ave velocity, left ventricular hypertrophy, and mortality in
aintenance dialysis populations (9,11).
The ankle brachial index (ABI) is a noninvasive measure
f subclinical CVD that may allow for determination of the
redominant pattern of arterial disease in the lower limbs. A
ow ABI is sensitive and specific for angiographically deter-
ined atherosclerosis of the lower extremities (15,16), and
s strongly associated with CVD events and mortality in a
ariety of populations (17–23). Alternatively, a high ABI
eflects generalized stiffening of the lower limb arteries
24,25), and an elevated ankle systolic blood pressure has
igh specificity for medial arterial calcification (26). Recent
tudies show U-shaped relationships between ABI and
ortality, wherein subjects with a high ABI had nearly
qual mortality risk to subjects with a low ABI, and both
roups were at approximately 2-fold mortality risk com-
ared with subjects with intermediate ABI scores (27–29).
Although prior studies have shown that CKD is associ-
ted with a low ABI (30–33), the association of CKD with
high ABI has not been studied. Such an association would
uggest that medial arterial calcification may begin early in
he process of kidney dysfunction. Herein, we evaluate the
ssociation of CKD with a high ABI and compare the
trength of association to that with a low ABI in the CHS
Cardiovascular Health Study), a community-based cohort
f older adults. We hypothesized that CKD would be
ssociated with both a low and a high ABI, independent of
raditional CVD risk factors.
ethods
articipants. The CHS is a community-based study of
lder adults that was designed to evaluate risk factors for
evelopment and progression of CVD. Its study design has
een described previously (34,35). In brief, eligibility re-
uired age 65 years, expectation to remain in the area for
years after recruitment, no active cancer treatment, and
he ability to provide consent. Between 1989 and 1990,
,201 participants were recruited from 4 communities (Sac-
amento, California; Forsyth County, North Carolina;
ashington County, Maryland; and Allegheny County,
ennsylvania). An additional 687 African Americans wereecruited in 1992 to 1993. Participants were sampled from iedicare eligibility lists in each
rea. The present study repre-
ents a cross-sectional analysis
sing data from the 1992 to 1993
tudy visit, at which ABI and
idney function were measured
oncurrently. Among the 5,265
ubjects who participated in that
isit, 488 (9%) were excluded
ecause of missing ABI measure-
ents, and 246 (5%) were ex-
luded because of missing kidney
unction measurement, resulting
n a study sample of 4,531 sub-
ects for this analysis. All partic-
pants provided written informed
onsent, and the study was approved by the investigational
eview boards of the 4 clinical sites and the Data Coordi-
ating Center at the University of Washington.
easurements. KIDNEY FUNCTION. Fasting (8 h) blood
pecimens were collected at the 1992 to 1993 study visit,
nd were stored at 70°C. Cystatin C concentrations were
easured using a BN II nephelometer (Dade Behring Inc.,
eerfield, Illinois) as described elsewhere (36). The intra-
ssay and interassay coefficients of variation were 2.9%
nd 3.2%, respectively. Cystatin C–based estimated glo-
erular filtration rate (eGFR) was calculated using the
quation: eGFRcys  76.7 · cystatin C [mg/l]
1.19 (37).
Serum creatinine concentrations were measured using the
odak Ektachem 700 Analyzer (Eastman Kodak, Roches-
er, New York), a colorimetric method. The intra-assay
oefficient of variation was 2%. Creatinine measurements
ere indirectly calibrated to the reference standard at the
leveland Clinical laboratory, the core laboratory of the
DRD (Modification of Diet and Renal Disease) study, as
reviously described (38). The abbreviated (4-variable)
DRD study formula was used to calculate creatinine-
ased eGFR (eGFRMDRD) (39). CKD was defined by an
GFR 60 ml/min/1.73 m2 by either equation (40).
BI. The ABI protocol has been described previously (20).
riefly, after at least 5 min rest and with the subject in a
upine position, standard mercury sphygmomanometers and
Doppler stethoscope (8 MHz, Huntleigh Technology,
nc., Luton, United Kingdom) determined the right bra-
hial artery and right and left leg posterior tibial artery
ystolic blood pressures. Duplicate measurements were ob-
ained and averaged. When a blood pressure could not be
easured in the right arm, the left arm was used. The ratio
f the systolic blood pressure in the leg to the arm defined
he leg-specific ABI. The lower of the leg-specific ABIs was
sed as the patient-specific ABI for this analysis. When
rterial flow was not abolished with the leg blood pressure
uff inflated to 300 mm Hg, the artery was deemed
Abbreviations
and Acronyms
ABI  ankle brachial index
CKD  chronic kidney
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
eGFR  estimated
glomerular filtration rate
HDL  high-density
lipoprotein
PAD  peripheral arterial
diseasencompressible.
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CKD and the Spectrum of ABI September 22, 2009:1176–84ECONDARY PREDICTORS. Age, sex, and race/ethnicity
ere determined by self report. After a 5-min rest, seated
lood pressure was determined in duplicate using standard
ercury sphygmomanometers (Hawksley & Sons Ltd.,
ussex, United Kingdom) (41). Results were averaged.
revalent hypertension was defined by a seated systolic
lood pressure 140 mm Hg, diastolic blood pressure 90
m Hg, or treatment for hypertension. Prevalent diabetes
as defined by history of physician’s diagnosis, use of
ypoglycemic agents or insulin, or fasting glucose level
126 mg/dl. Smoking history was determined by question-
aire and categorized as current, past, or never. Height (cm)
nd weight (kg) were recorded without shoes and with the
atient wearing light clothes, and body mass index was
alculated (kg/m2). The Olympus Demand System (Olym-
us, Lake Success, New York) determined serum total and
igh-density lipoprotein (HDL) cholesterol and triglyceride
oncentrations; low-density lipoprotein cholesterol concen-
rations were calculated using the Friedewald equation (42).
he C-reactive protein (CRP) was determined by an
ltrasensitive enzyme-linked immunosorbent assay as de-
cribed previously (43,44).
tatistical analysis. We developed natural piecewise-cubic
pline functions to evaluate parametric nonlinear functions for
GFRcys and ABI measurements. Pre-specified interior knots
ere placed at the quartiles of the distribution of eGFRcys.
ubjects with the 2.5% highest and lowest extreme eGFRcys
easurements were excluded from spline functions to avoid
linically implausible extrapolation by extreme values. Because
rior studies consistently showed higher risk for all-cause
ortality and CVD events among people with an ABI0.9 or
1.4 (27–29), we developed mutually exclusive categories that
imultaneously captured the functional form of the spline
nalysis and also utilized these cut points ( 0.90, 0.90 to 1.09,
.10 to 1.40, and 1.40/incompressible). Subjects with ABI
easurements of 1.10 to 1.40 served as the reference group for
ubsequent analyses.
We compared the distribution of demographic character-
stics and traditional CVD risk factors across ABI groups by
nalysis of variance for continuous variables and chi-square
or categorical variables. When statistically significant dif-
erences were observed across groups, pairwise comparisons
etween groups were evaluated by the Student t test or
ilcoxon rank sum test for continuous variables, and by the
hi-square test or Fisher exact test for categorical variables.
e adjusted for multiple comparisons using the Holm-
idak test (45).
Multinomial logistic regression evaluated the associations
f CKD with a low and high ABI simultaneously. It uses a
og-link rather than logit-link, and therefore provides esti-
ates of the relative risk. The initial model was unadjusted,
nd a subsequent model was adjusted for age, sex, and race.
he final model evaluated these variables and all other
ariables that were significantly different across ABI categories,
roviding a parsimonious list of covariates to facilitate
omparison of the relative strength of associations of CKD mith a high and low ABI. We performed sensitivity analyses
valuating ankle systolic blood pressure as the outcome,
djusting for the identical covariates and brachial blood
ressure, because previous studies provide test characteris-
ics of ankle blood pressure for medial arterial calcification
ather than the high ABI (26). Results were similar, so data
re presented for ABI only. Lastly, we created multiplicative
nteraction terms to evaluate whether the observed relation-
hips differed by diabetes status, selected a priori because of
rior published research (46,47). S-Plus (version 8.0) and
PSS statistical software (version 15.0.1.1) (SPSS, Inc.,
hicago, Illinois) were used for the analyses.
esults
mong the 4,513 study participants, the mean age was 75
ears, 58% were female, and 83% were Caucasian. The
ean eGFRcys was 73 19, and the mean eGFRMDRD was
6  20 ml/min/1.73 m2, respectively. Chronic kidney
isease was detected among 23% (n  1,042) by eGFRcys,
nd 21% (n  939) by eGFRMDRD. Thirteen percent of
articipants (n  579) had ABI measurements 0.90, 33%
n  1,478) had an ABI between 0.90 and 1.09, 51% (n 
,304) had an ABI between 1.10 and 1.40, and 3% (n 
52) had an ABI 1.40 or incompressible. Fifty-seven
articipants were categorized in this latter group on the
asis of incompressible lower limb arteries.
Compared with participants with an ABI 1.10 to 1.40,
ower ABI participants were older; more frequently male
nd African American; had a higher prevalence of hyper-
ension, diabetes, and tobacco use; and were more likely to
ave an atherogenic lipid profile and higher CRP levels
Table 1). In contrast, participants with a high ABI did not
iffer significantly by age or race. With the exception of
ale sex, diabetes, and lower HDL cholesterol, high ABI
as not associated with traditional CVD risk factors.
articipants with a high ABI had similar tobacco use and
ody mass index, and a lower prevalence of hypertension
nd lower total and low-density lipoprotein cholesterol,
riglycerides, and CRP levels compared with the reference
roup.
We evaluated the association of kidney function as a
ontinuous variable with ABI measurements. Adjusted
pline functions showed a U-shaped relationship, wherein
eople with either a high or low ABI had a lower eGFR
ompared with people with intermediate ABI measure-
ents (Fig. 1). Subjects with the most preserved kidney
unction (highest eGFR) were centered at an ABI measure-
ent of 1.20.
When defined by eGFRcys, CKD was associated with an
pproximately 3-fold risk of an ABI 0.90, and an approx-
mately 1.5-fold risk of an ABI 1.40 compared with
ubjects with ABI measurements of 1.10 to 1.40 in unad-
usted analyses (Table 2). The association of CKD with ABI
0.90 was moderately attenuated in the fully adjusted
odel, but CKD remained significantly associated with a
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September 22, 2009:1176–84 CKD and the Spectrum of ABI-fold risk of a low ABI. In contrast, statistical adjustment
or traditional CVD risk factors had a minimal effect on the
ssociation of CKD with an ABI 1.40. Results were
imilar when CKD was defined by creatinine, as well as in
ompanion analyses that evaluated ankle systolic blood
ressure as the dependent variable, rather than ABI (data
ot shown).
To determine the severity of CKD at which these
ssociations became evident, we evaluated the association of
idney function as a continuous measure with a low and
igh ABI. For each outcome, there was a modest linear
ssociation at early decrements in kidney function that
ecame generally steeper among subjects with eGFR values
80 ml/min/1.73 m2 (Fig. 2).
Next, we evaluated the association of each kidney func-
ion measure with the ABI categories, stratified by diabetes
tatus. The associations of CKD with a low ABI seemed
imilar in people with or without diabetes (Table 3). The
ssociation of CKD with a high ABI, however, was quali-
atively stronger among people with diabetes, and the
nteraction was of borderline significance for eGFRcys,
articipants Categorized by ABI*Table 1 Participants Categorized by ABI*
<0.90
n (%) 579 (13)
Demographics
Age (yrs) 77 6†
Female 292 (50)†
Race/ethnicity
White 410 (71)†
Black 163 (28)†
Other 6 (1)†
Medical history
Hypertension 428 (74)†
Diabetes 140 (24)†
Smoking
Current 96 (17)†
Past 284 (50)†
Never 189 (33)†
Measurements
Body mass index (kg/m2) 26.2 4.7
Systolic blood pressure (mm Hg) 144 24†
Diastolic blood pressure (mm Hg) 70 13†
Total cholesterol (mg/dl) 215 43
LDL cholesterol (mg/dl) 134 38†
HDL cholesterol (mg/dl) 50 14†
Triglycerides (mg/dl) 133 [94–194]†
C-reactive protein (mg/l) 3.9 [1.8–8.4]†
Kidney function
eGFRMDRD (ml/min/1.73 m
2) 71 24†
eGFRcys (ml/min/1.73 m
2) 64 20†
Cystatin C (mg/l) 1.27 0.47†
alues are n (%), mean  SD, or median [interquartile range]. *Across-group p values were 0.0
.05 compared with the ABI 1.10 to 1.40 category (Sidak adjusted).
ABI  ankle brachial index; eGFR  estimated glomerular filtration rate; HDL  high-density liplthough less so for eGFRMDRD (interaction p values  s.07 and  0.24, respectively). Because of the small num-
ers in the high ABI group, the power to detect such an
nteraction was low.
iscussion
he primary finding of this study is that moderate CKD is
ssociated with a high ABI in community-living older
eople. Participants with CKD had an approximately 50%
reater risk of a high ABI in adjusted models, an association
f approximately equal strength to the association of CKD
ith a low ABI. High ABI has predicted all-cause (27–29)
nd CVD mortality (28,29), stroke, and heart failure (29) in
rior studies. Therefore, the associations demonstrated here
ay provide novel insights into the underlying mechanisms
f arterial disease among people with CKD.
The association of kidney function with a high ABI was
vident at an eGFR of approximately 80 ml/min/1.73 m2 or
ower in this study. This observation may be important to
lucidating mechanisms linking early decrements in kidney
unction with CVD risk. A prior study from our group (3)
ABI
0–1.10 1.10–1.40 >1.40/Incompressible
78 (33) 2,304 (51) 152 (3)
5 5† 74 5 75 6
04 (68)† 1,266 (55) 54 (36)†
82 (80)† 1,980 (86) 135 (89)
89 (20)† 312 (14) 17 (11)
7 (1)† 12 (1) 0 (0)
19 (62)† 1,155 (50) 63 (41)‡
16 (15) 300 (13) 34 (22)†
79 (12)† 151 (7) 12 (8)
19 (43)† 1,007 (45) 74 (49)
45 (45)† 151 (7) 65 (43)
4 4.6† 27.2 4.7 27.1 5.2
0 22† 133 19 126 25†
2 12 71 11 68 11†
1 37† 207 37 195 38†
8 33 126 33 119 34
5 15† 53 14 51 13
[90–174] 122 [88–169] 117 [86–153]
[1.3–6.4]† 2.4 [1.1–5.3] 1.9 [0.9–4.7]
7 21 77 19 75 21
4 19 75 18 68 19†
9 0.28 1.08 0.30 1.21 0.55†
ll comparisons. †p  0.01 compared with the ABI 1.10 to 1.40 category (Sidak adjusted). ‡p 
in; LDL  low-density lipoprotein; MDRD  Modification of Diet and Renal Disease.0.9
1,4
7
1,0
1,1
2
9
2
1
6
6
26.
14
7
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5
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2.8
7
7
1.0
01 for ahowed that subjects with early decrements in kidney
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CKD and the Spectrum of ABI September 22, 2009:1176–84unction not sufficiently severe to result in elevated serum
reatinine levels were strongly associated with future CVD
vents in the CHS cohort. The mechanisms responsible for
his relatively strong association despite only modest decre-
ents in kidney function remain uncertain. Therefore, if the
ssociation of mild kidney dysfunction and a high ABI is
onfirmed, future studies elucidating the responsible mech-
nisms may provide novel insights into the link between
KD and CVD events.
Medial arterial calcification is thought to lead to high
BI measurements in the majority of cases (24,25).
ndeed, Young et al. (26) showed that high ABI scores
irectly correlated with medial arterial calcification sever-
ty as determined by lower limb plain X-ray, and that an
Figure 1 Estimated GFR by Ankle-Brachial Index
A natural cubic spline function. The solid line represents mean adjusted glomerular fil
spline function was adjusted for age, sex, race, hypertension, diabetes, smoking, bod
ssociations of CKD* With High and Low ABITable 2 Associations of CKD* With High and Low ABI
<0.90
n (%) 579 (13)
Moderate CKD by cystatin-based eGFR (n  1,042, 23%)
Unadjusted 3.07 (2.53–3.74
Age, sex, race adjusted 2.55 (2.06–3.15
Fully adjusted† 2.00 (1.60–2.51
Moderate CKD by MDRD-based eGFR (n  936, 21%)
Unadjusted 2.12 (1.73–2.61
Age, sex, race adjusted 1.83 (1.48–2.28
Fully adjusted† 1.59 (1.26–2.01
alues are relative risk (95% confidence interval) unless otherwise specified. *Defined as eGFR 
RP.
BMI  body mass index; CKD  chronic kidney disease; CRP  C-reactive protein; other abbreviationsnkle systolic blood pressure 190 mm Hg had 90%
pecificity for X-ray– determined medial arterial calcifi-
ation. Medial arterial calcification is characterized by a
iffuse distribution that may directly contribute to arterial
tiffness (13,14,48,49). Among maintenance dialysis pa-
ients, medial arterial calcification has been associated
ith increased left ventricular mass and aortic pulse-wave
elocity (13), which may lead to cardiac fibrosis and
ncreased arrhythmia risk. If similar relations extend to
eople without severe kidney disease, a high ABI might
ndicate elevated risk for CVD events and mortality by
echanisms entirely distinct from atherosclerosis. These
ypotheses require future study, but may be particularly
elevant in people with CKD, in whom the prevalence of
rate (GFR), and dotted lines represent 95% confidence intervals. The
index, low-density lipoprotein, high-density lipoprotein, and C-reactive protein.
ABI Groups
0.90–1.10
1.10–1.40
(Reference) >1.40/Incompressible
1,478 (33) 2,304 (51) 152 (3)
1.22 (1.03–1.43) — 1.65 (1.14–2.38)
1.18 (1.00–1.40) — 1.57 (1.06–2.32)
1.11 (0.93–1.33) — 1.55 (1.04–2.33)
1.19 (1.01–1.41) — 1.43 (0.97–2.10)
1.13 (0.96–1.34) — 1.45 (0.97–2.16)
1.07 (0.90–1.28) — 1.50 (1.00–2.24)
min/1.73 m2. †Adjusted for age, sex, race, hypertension, diabetes, smoking, BMI, LDL, HDL, andtration
y mass)
)
)
)
)
)
60 ml/as in Table 1.
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September 22, 2009:1176–84 CKD and the Spectrum of ABIrterial calcification is high (50,51) and in whom tradi-
ional CVD risk factors only partially account for CVD
isk (2,52).
Although a high ABI may identify individuals at higher
isk for CVD events, it is uncertain whether or not this
ssociation is entirely independent of atherosclerosis. Ath-
rosclerotic peripheral arterial disease (PAD) and medial
rterial calcification may coexist within individuals (53,54).
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Figure 2 The Association of the Spectrum of GFR With Low an
Natural cubic spline function. The solid line represents relative risk, and dotted lin
sex, race/ethnicity, hypertension, diabetes, smoking, body mass index, low-densit
Figure 1.hen this occurs, the stiff lower limb arteries may increase mhe ABI measurements, thus precluding the detection of
therosclerotic disease via a low ABI. Therefore, the asso-
iations of a high ABI with CKD in this analysis, and with
VD events and all-cause mortality in prior reports, may in
art reflect residual confounding by undetected peripheral
therosclerosis. Future studies with confirmatory tests for
therosclerotic PAD that are less affected by concomitant
edial arterial calcification, such as toe brachial index
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CKD and the Spectrum of ABI September 22, 2009:1176–84ions of medial arterial calcification to CVD events, inde-
endent of atherosclerosis.
With the exception of age, diabetes, and lower HDL,
raditional CVD risk factors were not associated with a high
BI in this study. Similar findings have been observed in
ther community-based studies (28,29). Future research
hould evaluate risk factors for high ABI and, by extension,
isk factors for arterial stiffness. Small studies among people
ith advanced CKD have suggested that alterations in
ineral metabolism may be associated with medial arterial
alcification or a high ABI (13,55). Whether or not such
ssociations extend to populations with normal to moderate
ecrements in kidney function is unknown. In addition,
uture studies should evaluate the associations of a high ABI
ith cardiac structure and function, both at rest and with
tress, because prior studies suggest that subjects with a high
BI may have a more pronounced vasoreactive response to
xercise (56).
Strengths of this study include its community-based
etting, large sample size, and uniform measurement of
reatinine, cystatin C, ABI, and multiple potential con-
ounding variables. The simultaneous availability of creati-
ine and cystatin C has specific advantages. The eGFR by
reatinine is commonly available in clinical practice and
any observational studies, improving the generalizability
f our study and allowing comparison of strengths of
ssociation across studies if these associations are evaluated
n other settings in the future. Alternatively, cystatin C
rovides a more accurate measure of kidney function among
eople with normal or near-normal kidney function
57–60), the range of kidney function observed in the
ajority of CHS study participants. Its availability in this
tudy allows us to evaluate more accurately whether or not
arly decrements in kidney function were associated with a
igh and low ABI.
This study also has important limitations. First, the
ross-sectional study design does not allow evaluation of
ssociation of CKD With High and Low ABI, Stratified by DiabetesTable 3 Association of CKD With High and Low ABI, Stratified
<0.90
Moderate CKD by cystatin* (n  1,042, 23%)
Diabetes, n (%) 56 (40)
Adjusted association† 1.78 (1.04–3.05)
No diabetes, n (%) 185 (42)
Adjusted association† 2.08 (1.62–2.68)
Interaction p values (cystatin [continuous]* DM) 0.60
Moderate CKD by MDRD* (n  936, 21%)
Diabetes, n (%) 38 (27)
Adjusted association† 1.43 (0.82–2.49)
No diabetes, n (%) 145 (33)
Adjusted association† 1.63 (1.27–2.11)
Interaction p values (MDRD [continuous]* DM) 0.84
alues are relative risk (95% confidence interval) unless otherwise specified. *Defined as eGFR 
DM  diabetes mellitus; other abbreviations as in Table 2.emporality. Next, we lacked albuminuria measurements. A crior study showed that albuminuria was associated with a
igh ABI in bivariate analysis, but this was not subjected to
ultivariable models, an area that requires further investi-
ation (61). The ABI was defined by right arm blood
ressures and without dorsalis pedis blood pressures. This
ay have introduced some misclassification in ABI catego-
ies. Future studies should include both ABI and toe
rachial index measurements to evaluate more completely
he respective associations of atherosclerotic PAD and
rterial stiffness with CVD events. Next, because the prev-
lence of a high ABI was only 3% (n  152) in our study
ample, we had imprecise estimates of strengths of associ-
tion, as shown by relatively wide confidence intervals
Table 2). This was particularly true when analyses were
tratified by diabetes status. Although the association of
KD with a high ABI was qualitatively stronger in people
ith diabetes, future studies are required to determine
hether this observation is reproducible. Last, participants
n this study were older and were community-living, and
ew had advanced CKD. Results may not be generalizable to
ounger people or to those with late-stage CKD.
onclusions
e show that diminished kidney function is associated with
igh ABI measurements. The relationship of kidney func-
ion with a high ABI was not explained by traditional CVD
isk factors. Although much is known about risk factors and
onsequences of atherosclerotic PAD, future studies are
eeded to elucidate mechanisms leading to high ABI and
edial arterial calcification and to understand mechanisms
inking them to CVD events. Such studies may ultimately
rovide novel insights into the mechanisms of CVD in
ubjects with kidney disease.
cknowledgments
full list of principal CHS investigators and institutions
sabetes Status
ABI Groups
0.90–1.10 1.10–1.40 >1.40/Incompressible
56 (26) 65 (22) 14 (41)
1.03 (0.63–1.68) — 3.94 (1.71–9.09)
269 (21) 369 (18) 28 (24)
1.12 (0.92–1.36) — 1.15 (0.71–1.85)
0.65 — 0.07
44 (20) 50 (17) 10 (29)
1.07 (0.64–1.77) — 2.56 (1.11–5.90)
261 (21) 362 (18) 26 (22)
1.06 (0.88–1.28) — 1.26 (0.79–2.00)
0.61 — 0.27
min/1.73 m2. †Adjusted for age, sex, race, hypertension, smoking, BMI, LDL, HDL, and CRP.Statuby Dian be found at http://www.chs-nhlbi.org/pi.htm.
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